| pubmed-article:8834057 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8834057 | lifeskim:mentions | umls-concept:C0063710 | lld:lifeskim |
| pubmed-article:8834057 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:8834057 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:8834057 | lifeskim:mentions | umls-concept:C1555307 | lld:lifeskim |
| pubmed-article:8834057 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8834057 | pubmed:dateCreated | 1996-12-11 | lld:pubmed |
| pubmed-article:8834057 | pubmed:abstractText | Most rheumatic diseases resist traditional therapeutic interventions. Novel biologicals show considerable promise as antirheumatic agents but do not lend themselves to delivery as drugs. Gene therapy promises to harness the therapeutic potential of proteins by acting as a biological drug delivery system. Considerable progress has been made in the use of genes to treat animal models of RA, and a human trial of this technology is scheduled to begin this year. | lld:pubmed |
| pubmed-article:8834057 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8834057 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8834057 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8834057 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8834057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8834057 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8834057 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8834057 | pubmed:issn | 1081-650X | lld:pubmed |
| pubmed-article:8834057 | pubmed:author | pubmed-author:EvansC HCH | lld:pubmed |
| pubmed-article:8834057 | pubmed:author | pubmed-author:RobbinsP DPD | lld:pubmed |
| pubmed-article:8834057 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8834057 | pubmed:volume | 108 | lld:pubmed |
| pubmed-article:8834057 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8834057 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8834057 | pubmed:pagination | 1-5 | lld:pubmed |
| pubmed-article:8834057 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8834057 | pubmed:meshHeading | pubmed-meshheading:8834057-... | lld:pubmed |
| pubmed-article:8834057 | pubmed:meshHeading | pubmed-meshheading:8834057-... | lld:pubmed |
| pubmed-article:8834057 | pubmed:meshHeading | pubmed-meshheading:8834057-... | lld:pubmed |
| pubmed-article:8834057 | pubmed:meshHeading | pubmed-meshheading:8834057-... | lld:pubmed |
| pubmed-article:8834057 | pubmed:meshHeading | pubmed-meshheading:8834057-... | lld:pubmed |
| pubmed-article:8834057 | pubmed:meshHeading | pubmed-meshheading:8834057-... | lld:pubmed |
| pubmed-article:8834057 | pubmed:meshHeading | pubmed-meshheading:8834057-... | lld:pubmed |
| pubmed-article:8834057 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8834057 | pubmed:articleTitle | The promise of a new clinical trial--intra-articular IL-1 receptor antagonist. | lld:pubmed |
| pubmed-article:8834057 | pubmed:affiliation | Department of Orthopedic Surgery, University of Pittsburgh School of Medicine, PA 15261, USA. | lld:pubmed |
| pubmed-article:8834057 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8834057 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8834057 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:8834057 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8834057 | lld:pubmed |
